Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/7857
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSantos, Fabiane Matos dos-
dc.contributor.authorLima, Wanderson Geraldo de-
dc.contributor.authorGravel, André da Silva-
dc.contributor.authorMartins, Tassiane Assíria Fontes-
dc.contributor.authorSilva, André Talvani Pedrosa da-
dc.contributor.authorTorres, Rosália Morais-
dc.contributor.authorBahia, Maria Terezinha-
dc.date.accessioned2017-06-02T16:44:20Z-
dc.date.available2017-06-02T16:44:20Z-
dc.date.issued2012-
dc.identifier.citationSANTOS, F. M. et al. Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease. Journal of Antimicrobial Chemotherapy, v. 67, p. 1987-1995, 2012. Disponível em: <https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dks135>. Acesso em: 19 fev. 2017.pt_BR
dc.identifier.issn 0305-7453-
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/7857-
dc.description.abstractObjectives: To evaluate the effects of benznidazole on Chagas’ disease cardiac prognosis using an experimental dog model of infection. Methods: A total of 28 dogs were divided into three groups: 10 were infected with Trypanosoma cruzi and treated benznidazole during the chronic phase, 10 were infected but untreated, and 8 were non-infected/ healthy. The trypanocidal efficacy was measured by parasite kDNA detection in blood and cardiac tissue samples. The effects of benznidazole in ameliorating the cardiac systolic function were evaluated by echodopplercardiogram. Results: The benznidazole initially induced a potent suppression of parasitaemia in treated animals. However, 12 months post-treatment, the parasite kDNA detections were similar between infected groups. In the baseline echocardiographic parameters there was no variation among all animals. Similarly, 1 month post-treatment there was no significant difference among healthy and infected animals with regard to systolic function. At 12 months post-treatment, an increase in cardiac chamber size related to cardiomegaly was detected among treated and untreated animals, but not in the healthy controls. Interestingly, in spite of both groups of infected animals developing a decrease in their systolic cardiac function, this decline was slightly less in the treated animals. We also evaluated levels of tumour necrosis factor-a and interleukin-10 in peripheral blood mononuclear cell culture supernatant. Cytokine profiles were similar between infected animal groups and correlated with alterations in cardiac function. Conclusions: The temporary suppression of the T. cruzi infection induced by benznidazole treatment was efficient in reducing systolic cardiac function alterations, but not in preventing the development of cardiomyopathy.pt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectDog modelpt_BR
dc.subjectEchocardiographypt_BR
dc.titleCardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease.pt_BR
dc.typeArtigo publicado em periodicopt_BR
dc.identifier.uri2https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dks135pt_BR
dc.identifier.doihttps://doi.org/10.1093/jac/dks135-
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_CardiomyopathyPrognosisBenznidazole.pdf453,31 kBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.